Ariad Pharmaceuticals (NASDAQ:ARIA) is a company whose shares are active, trading 4.8% higher to $20.10. The S&P is currently trading 1.8% higher to 1,452 and the Dow Jones Industrial Average is trading 1.8% higher to 13,339.
Ariad Pharmaceuticals share prices have moved between a 52-week high of $25.40 and a 52-week low of $12.26 and are now trading 64% above that low price at $20.10 per share. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.7% while the 200-day MA has risen 0.5%.
Ariad Pharmaceuticals has overhead space with shares priced $20.10, or 30.4% below the average consensus analyst price target of $28.88. The stock should find resistance at its 50-day moving average (MA) of $21.57, as well as support at its 200-day MA of $19.27.
ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.